Figure 1. Comparative efficacy and representative photos of AD patients in <6 and 6-12 years old groups after treatment with dupilumab. (A) Efficacy outcomes compared with the respective baseline values over time. Patients treated with dupilumab from T0. Differences of data were assessed by Kruskal–Wallis signed-rank test. (B) Proportion of patients achieving EASI-50, 75, 90, IGA 0/1 at week-4, 8, 12 and 16 after treatment with dupilumab. Differences of data were assessed by Chi-squared test. (C) Skin lesions of a 2-year-old patient and (D) another 8-year-old patient at baseline (left panel) and at week-12 after treatment with dupilumab (right panel). Ns, no significance, *P<0.05, **P<0.01, ***P<0.001, compared between <6 and ≥6 years.